What matters when choosing advanced Parkinson's treatment?

Inclusion criteria: 1) Diagnosis of Parkinson's Disease (confirmed by a physician) 2) Adults (30 years of age or older) 3) Receiving PD treatment (oral medications and/or applied therapy) in Japan 4) Patients who meet any of the 5-2-1 criteria (defined by physicians) a. Taking oral levodopa five or more times per day b. Off time for more than 2 hours per day c. Troublesome dyskinesia for more than 1 hour per day 5) Able to respond to this survey by themselves (assistance for entering their answers to the web-based questionnaire by their caregivers is allowed) 6) Given consent to the study Exclusion criteria: 1) Patients with experience in any device-aided therapy (DATs; CSCI, LCIG, or DBS) or FUS 2) Patients with impaired cognitive function (e.g., MMSE under 23, taking medicine for Alzheimer's disease or cognitive impairment (specifically: donepezil HCl, rivastigmine transdermal system, galantamine, galantamine HBr, memantine HCI)), or psychosis (either past history or current) 3) Patients with a diagnosis of atypical or secondary Parkinsonism 4) Patients with visual impairment significant enough that they cannot comply with the study procedures 5) Did not provide consent to participate (and record the interview) 6) Is not willing nor able to comply with procedures required in this protocol 7) Patients who are pregnant 8) Not fluent in Japanese